Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Cassaday, Ryan D
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
D
Lynch RC
,
Cassaday RD
,
Smith SD
,
Fromm JR
,
Cowan AJ
,
Warren EH
,
Shadman MS
,
Shustov A
,
Till BG
,
Ujjani CS
, et al.
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lancet Haematol. 2021;8(8):e562-e571.
PubMed
Google Scholar
H
Krakow EF
,
Brault M
,
Summers C
,
Cunningham TM
,
Biernacki MA
,
R Black G
,
Woodward KBlake
,
Vartanian N
,
Kanaan SB
,
Yeh AC
, et al.
HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Blood. 2024.
PubMed
Google Scholar
DeFilipp Z
,
Advani AS
,
Bachanova V
,
Cassaday RD
,
DeAngelo DJ
,
Kebriaei P
,
Rowe JM
,
Seftel MD
,
Stock W
,
Tallman MS
, et al.
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
Biol Blood Marrow Transplant. 2019.
PubMed
Google Scholar
I
Shah BD
,
Cassaday RD
,
Park JH
,
Houot R
,
Oluwole OO
,
Logan AC
,
Boissel N
,
Leguay T
,
Bishop MR
,
Topp MS
, et al.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
J Immunother Cancer. 2023;11(8).
PubMed
Google Scholar
K
Shah BD
,
Ghobadi A
,
Oluwole OO
,
Logan AC
,
Boissel N
,
Cassaday RD
,
Leguay T
,
Bishop MR
,
Topp MS
,
Tzachanis D
, et al.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Lancet. 2021.
PubMed
Google Scholar
O
Marks DI
,
Kebriaei P
,
Stelljes M
,
Gökbuget N
,
Kantarjian H
,
Advani AS
,
Merchant A
,
Stock W
,
Cassaday RD
,
Wang T
, et al.
Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia.
Biol Blood Marrow Transplant. 2019.
PubMed
Google Scholar
P
Cowan AJ
,
Stevenson PA
,
Cassaday RD
,
Graf SA
,
Fromm JR
,
Wu D
,
Holmberg LA
,
Till BG
,
Chauncey TR
,
Smith SD
, et al.
Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission.
Biol Blood Marrow Transplant. 2015.
PubMed
Google Scholar